Browsing publications by Professor Ruth Plummer

Newcastle AuthorsTitleYearFull text
Dr Rachel Pearson
Dr Peter Thelwall
Jim Snell
Dr Piotr Pieniazek
Dr Rakesh Heer
et al.
Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Laura Ogle
Dr James Orr
Catherine Willoughby
Dr Claire Hutton
Dr Stuart McPherson
et al.
Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Ashleigh McConnell
Dr Robert Ellis
Professor Ruth Plummer
Professor Penny Lovat
Dr Graeme O'Boyle
et al.
The prognostic significance and impact of the CXCR4/CXCR7/CXCL12 axis in primary cutaneous melanoma2016
Dr Yvette Drew
Dr Alastair Greystoke
Professor Ruth Plummer
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).2015
Dr Manolo D'Arcangelo
Professor Ruth Plummer
A first-in-human study of intravenous BAL101553, a novel microtobule inhibitor, in patients with advanced solid tumors2015
Professor Ruth Plummer
A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors2015
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors2015
Professor Ruth Plummer
Dr Jane Margetts
Professor John Lunec
Dr Joyce Nutt
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker2015
1234567891011121314